announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection. Tetra's research demonstrated that the class II medical device or pipe used to combust the PPP001 drug pellet generates a unique composition of medicinal ingredients. This composition is significantly different from that created when heating the drug pellet in a vaporizer. The data demonstrated that the drug produced by combustion is different from that of the vapor and may partly explain the recognized efficacy of smoked cannabis. The composition of the remaining chemicals was expected to be different between smoke and vapor. This led the Corporation to implement two separate drug development paths and allow Tetra to commence developing second generation drugs for inhalation. The patent covers methods of fabrication and composition of matter.